{
  "_metadata": {
    "version": "2.1",
    "ticker": "ASND",
    "asset_name": "palopegteriparatide_yorvipath_transcon_pth"
  },
  "asset": {
    "name": "Palopegteriparatide_YORVIPATH_TransCon_PTH",
    "company": "Ascendis Pharma A/S",
    "ticker": "ASND",
    "target": "PTH receptor",
    "mechanism": "Prodrug of PTH (1-34) that provides active PTH within physiological range for 24 hours per day through transient conjugation technology",
    "modality": "Prodrug using TransCon technology",
    "partner": null,
    "stage": "Approved",
    "one_liner": "Approved once-daily TransCon PTH prodrug (palopegteriparatide) for hypoparathyroidism in adults, providing physiological PTH levels around the clock"
  },
  "target": {
    "name": "PTH Receptor (PTH1R)",
    "biology": {
      "simple_explanation": "The PTH receptor (PTH1R) mediates the effects of parathyroid hormone on calcium and phosphate homeostasis. In hypoparathyroidism, insufficient PTH production leads to low calcium and high phosphate levels. Palopegteriparatide is a TransCon prodrug that continuously releases PTH(1-34) to restore physiological PTH signaling and normalize calcium metabolism."
    }
  },
  "clinical_development": {
    "current_stage": "Approved",
    "indications_in_development": [
      "Hypoparathyroidism in adults"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    4
  ],
  "_last_extracted": "2026-02-04T13:32:19.645957"
}